Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting
Current Oncology · 2025
DOI: 10.3390/curroncol32060296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Ibraheem Othman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine, Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Background
Long-term clinical trials and real-world data have established a comprehensive risk–benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy.
Methods
We retrospectively assessed the incidence of AEs of special interest and management strategies in all patients treated with ibrutinib for chronic lymphocytic leukemia (CLL) in Saskatchewan, Canada, since 2014.
Results
Among 187 patients (median age 75.7 years, 63% male), the median time from ibrutinib treatment initiation to data cutoff was 3.1 years. Approximately two-thirds of patients received ibrutinib for relapsed CLL (33.7% second-line and 32.6% third-line and beyond), with 33.7% receiving it first-line. All patients initiated ibrutinib as monotherapy at 420 mg. AEs of interest were observed in 81.3% of patients, with 42.8% experiencing ≥2 AEs. No grade 5 AEs were reported. Among the 284 first-onset AEs observed in 152 patients, 90.8% were successfully managed, allowing treatment continuation. The median time to successful management ranged from 27.0 days (range: 12.5–73.0) for infections to 84.0 days (range: 55.0–141.0) for hypertension. Both AE and discontinuation rates were comparable or favourable to previous reports.
Conclusion
This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada.
- College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
- Epidemiology and Performance Measurement, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada.
- Research Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, Canada.
- Department of Critical Care, Saskatchewan Health Authority, Regina, SK S4P 0W5, Canada.
- Division of Hematology, Department of Medical Oncology and Hematology, Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada.
ORCID-Profile: Ibraheem Othman, Yi Sin Chang, Eric Sy, Waleed Sabry
Förderung
- Johnson & Johnson Innovative Medicine
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Othman, I., Moossavi, S. Z. M., Bayati, S., Chang, Y. S., Sanjoy, S., Grzyb, K., Sy, E., Cropper, K., Kassir, S., & Sabry, W. (2025). Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology. https://doi.org/10.3390/curroncol32060296
Vancouver
Othman I, Moossavi SZM, Bayati S, Chang YS, Sanjoy S, Grzyb K, et al. Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting. Current Oncology. 2025. doi:10.3390/curroncol32060296
BibTeX
@article{Othman2025,
author = {Othman, Ibraheem and Moossavi, Seyedeh Zahra Mona and Bayati, Samaneh and Chang, Yi Sin and Sanjoy, Shubrandu and Grzyb, Karolina and Sy, Eric and Cropper, Kayla and Kassir, Sandy and Sabry, Waleed},
title = {Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32060296}
}
EUVIMED